Sep. 12, 2023—The Vanderbilt Prize Discovery Lecture featuring Professor Dame Frances Ashcroft, which was scheduled for Thursday, September 14, has been postponed until the spring of 2024. Details will be shared soon. Check the Discovery Lecture website at https://www.vumc.org/discovery-lecture-series/upcoming-lectures.
Sep. 6, 2023—Vanderbilt researchers have uncovered a potential new way to help curb the rapidly rising worldwide prevalence of metabolic disorders, including obesity and diabetes.
Sep. 6, 2023—Renowned diabetes expert Professor Dame Frances Ashcroft, recipient of the 2023 Vanderbilt Prize in Biomedical Science, will deliver her Vanderbilt Prize Discovery Lecture at 4 p.m. Thursday, Sept. 14, in 208 Light Hall.
Aug. 2, 2023—Researchers at Vanderbilt University Medical Center have received a four-year, $28 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to study the relationship between COVID-19 and diabetes.
Aug. 2, 2023—Griffin Rodgers, MD, director of the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, described the urgency of the nation’s diabetes epidemic July 26 during a symposium of the NIDDK Medical Student Research Program in Diabetes and Obesity hosted by Vanderbilt University.
Jun. 14, 2023—Ideas for addressing the disproportionate impact of cancer, diabetes, and gastrointestinal diseases on disadvantaged populations were shared recently during a diversity symposium at Vanderbilt University Medical Center.
May. 8, 2023—Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.
Apr. 6, 2023—Vanderbilt recently collaborated with Charis Health Center in Wilson County to create a Diabetes Education Toolkit to better serve Charis' patient population.
Mar. 23, 2023—A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.
Mar. 23, 2023—Vanderbilt's Diane Saunders, PhD, has been selected as a 2023 recipient of an Innovation Award by the Network of Pancreatic Donors with Diabetes.
Mar. 15, 2023—Professor Dame Frances Ashcroft, a British physiologist known internationally for her work on insulin secretion, Type 2 diabetes and neonatal diabetes, is the recipient of the 2023 Vanderbilt Prize in Biomedical Science.